Aegerion Pharmaceuticals Announces Pricing of Initial Public Offering

        Print
| Source: Aegerion Pharmaceuticals, Inc.

BRIDGEWATER, N.J., Oct. 22, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at $9.50 per share, before underwriting discounts and commissions. All shares are being sold by the company. Aegerion has granted the underwriters an option for 30 days to purchase up to an additional 750,000 shares at the initial public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. The common stock will trade on the NASDAQ under the symbol "AEGR."

Leerink Swann LLC and Lazard Capital Markets LLC are acting as joint book-running managers for the offering. Needham & Company, LLC, Canaccord Genuity Inc. and Collins Stewart LLC are acting as co-managers for the offering.

A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from Leerink Swann LLC by mail at One Federal Street, 37th Floor, Boston, MA 02110, Attention: Syndicate Department, or by calling toll free (800) 808-7525, Ext. 4814, or Lazard Capital Markets LLC by mail at 30 Rockefeller Plaza, 60th Floor, New York, NY 10020, Attention: Syndicate Department, or by calling toll free (800) 542-0970.

About Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals (Nasdaq:AEGR) is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. The Company's lead product candidate is a small molecule, oral therapy being developed for patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH.

Aegerion Pharmaceuticals, Inc
Corporate
Will Lewis, President
+1 (908) 704-1300

LaVoie Group, Inc.
Investors & Media
Liz Pingpank
+1 (978) 745-4200 x104